Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo

Histone deacetylase (HDAC) inhibitors have received considerable attention as potential therapeutics for a variety of cancers and neurological disorders. Recent publications on a class of pimelic diphenylamide HDAC inhibitors have highlighted their promise in the treatment of the neurodegenerative d...

Descripción completa

Detalles Bibliográficos
Autores principales: Beconi, Maria, Aziz, Omar, Matthews, Kim, Moumné, Lara, O’Connell, Catherine, Yates, Dawn, Clifton, Steven, Pett, Hannah, Vann, Julie, Crowley, Lynsey, Haughan, Alan F., Smith, Donna L., Woodman, Ben, Bates, Gillian P., Brookfield, Fred, Bürli, Roland W., McAllister, George, Dominguez, Celia, Munoz-Sanjuan, Ignacio, Beaumont, Vahri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433414/
https://www.ncbi.nlm.nih.gov/pubmed/22973455
http://dx.doi.org/10.1371/journal.pone.0044498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433414/
https://www.ncbi.nlm.nih.gov/pubmed/22973455
http://dx.doi.org/10.1371/journal.pone.0044498

Ejemplares similares